Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from N4 Pharma ( (GB:N4P) ) is now available.
N4 Pharma announced the posting of a circular and notice of a General Meeting to discuss a proposed Placing and Subscription. This meeting, scheduled for April 22, 2025, is a strategic step for the company as it seeks to advance its financial and operational goals, potentially impacting its market positioning and stakeholder interests.
More about N4 Pharma
N4 Pharma is a pre-clinical biotech company focused on developing Nuvec®, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The company is working towards securing significant licensing deals for its Nuvec® platform with gene therapy partners, with a lead program, N4 101, serving as a proof-of-concept for its capabilities.
YTD Price Performance: -18.27%
Average Trading Volume: 2,358,259
Technical Sentiment Signal: Strong Buy
Current Market Cap: £4.61M
For a thorough assessment of N4P stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue